Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Attempts to optimize active specific immunotherapy for melanoma.

M S Mitchell1

  • 1Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.

International Reviews of Immunology
|January 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The treatment of disseminated vasculitis with methotrexate.

Inflammation·2013
Same author

The N-terminal ATPase site in the large terminase protein gp17 is critically required for DNA packaging in bacteriophage T4.

Journal of molecular biology·2002
Same author

Optimization of intracerebral tumour protection by active-specific immunization against murine melanoma B16/G3.12.

Melanoma research·2001
Same author

A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes.

Cancer research·2000
Same author

Synthetic insertion signal sequences enhance MHC class I presentation of a peptide from the melanoma antigen MART-1.

European journal of immunology·2000
Same author

The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer.

Seminars in oncology·1999

A melanoma therapeutic vaccine (theraccine) demonstrated a 20% objective clinical response rate, slowing disease progression and increasing survival. Immune responses, including cytotoxic T lymphocyte precursors (pCTL), correlated with clinical outcomes in melanoma patients.

Area of Science:

  • Oncology
  • Immunology
  • Vaccine Development

Background:

  • Melanoma remains a significant health concern, necessitating novel therapeutic strategies.
  • Current treatments have limitations, driving research into immunotherapy.
  • Therapeutic cancer vaccines offer a promising approach to stimulate anti-tumor immunity.

Purpose of the Study:

  • To evaluate the efficacy and immunogenicity of a novel therapeutic melanoma vaccine (theraccine).
  • To assess the impact of the vaccine on clinical response, survival, and immune markers.
  • To explore the role of T lymphocytes and HLA associations in vaccine response.

Main Methods:

  • Clinical trials involving subcutaneous injection of a melanoma vaccine (cell lysates + DETOX adjuvant).
  • Monitoring of objective clinical regression, survival rates, and immune responses (pCTL, CD4+, CD8+ CTL).

Related Experiment Videos

  • Analysis of HLA phenotypes and their association with clinical response.

    • Main Results:

    • 20% objective clinical regression (5% complete response) observed in 109 patients.
    • Increased survival noted, with 10 patients living over a year (5 living >3 years).
    • Correlation between increased pCTL levels and clinical response; CD4+ and CD8+ CTL demonstrated specific anti-melanoma activity.

    Conclusions:

    • The melanoma theraccine shows clinical efficacy in slowing disease progression and improving survival.
    • Immune responses, particularly pCTL and specific CTL activity, are associated with therapeutic benefit.
    • Further investigation into HLA associations may refine patient selection and vaccine design.